ArticleAdvances in urology2026
Efficacy of Levocetirizine in Reducing Double-J Stent-Related Symptoms: A Double-Blind Pilot Randomized Controlled Trial.
Article in Advances in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Levocetirizine in Reducing Double-J Stent-Related Symptoms: A Double-Blind Pilot Randomized Controlled Trial.Advances in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study is to evaluate the safety and efficacy of levocetirizine in reducing ureteral stent-related symptoms. Methods: In this single-center randomized controlled trial, 85 patients requiring double-J stent placement, 3 patients were excluded and 82 were allocated to start preoperatively levocetirizine 5 mg daily (Group B Results: Out of 82 participants included, three patients were excluded before analysis due to loss to follow-up or hospitalized for UTI that mimics stent-related symptoms. 79 patients were considered for final analysis. Group B showed a statistically significant reduction in stent-related morbidity USSQ across all subgroups compared to the placebo group and a lower VAS pain score ( Conclusion: This pilot study indicates that levocetirizine effectively reduces stent-related symptoms and maintains a good safety profile. These findings suggest that levocetirizine may be a well-tolerated adjunct therapy for managing stent discomfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.